Oregon Life Science Industry Directory

Target your advertising by state, region or nationwide for the same low rate

Banner Advertising | Event Advertising

Exelixis, Inc.

Exelixis, Inc. 210 East Grand Avenue PO Box 511 S. San Francisco, CA 94080-0511

Phone: (650) 837-7000 Fax: (650) 837-8300 Year Established:   2000 Ticker: EXEL Exchange: NASDAQ Main Contact: J. Scott Garland, Executive VP & CCO   Other Contacts:   Andrew R. Peters, VP, Strategy Gregg Bernier, VP of Marketing William Berg, M.D., Senior VP, Medical Affairs Gisela M. Schwab, MD, Executive VP & CMO Jeffrey J. Hessekiel, J.D., Executive VP & General Counsel Peter Lamb, Ph.D., Executive VP, Discovery Research & CSO Chris Senner, Executive VP & CFO Michael Morrissey, Ph.D,, President & CEO Stefan Krauss, Ph.D., VP, Business Development   Company Description Exelixis is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, Sanofi-Aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo.

Main Industry Directory